Friday, 29 March 2024


Australia gives recognition to India's Covaxin & China's Sinopharm COVID-19 vaccine

01 November 2021 | News

TGA recognises two more COVID-19 vaccines not registered in Australia but used widely internationally

image credit- shutterstock

image credit- shutterstock

The Therapeutic Goods Administration (TGA) in Australia has determined that Covaxin (manufactured by Bharat Biotech, India) and BBIBP-CorV (manufactured by Sinopharm, China) vaccines would be 'recognised' for the purpose of establishing a traveller's vaccination status.

This recognition is for travellers aged 12 and over who have been vaccinated with Covaxin, and those 18 to 60 who have been vaccinated with BBIBP-CorV.

In recent weeks, the TGA has obtained additional information demonstrating these vaccines provide protection and potentially reduce the likelihood that an incoming traveller would transmit COVID-19 infection to others while in Australia or become acutely unwell due to COVID-19.

The supporting information has been provided to the TGA from the vaccine sponsor and/or the World Health Organisation.

Importantly, recognition of Covaxin, and BBIBP-CorV, along with the previously announced recognition of Coronavac (manufactured by Sinovac, China) and Covishield (manufactured by AstraZeneca, India), means many citizens of China and India as well as other countries in Australia where these vaccines have been widely deployed will now be considered fully vaccinated on entry to Australia.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account